OncoAssure collaborates with leading US medical centre on prostate cancer study
NovaUCD-based medtech OncoAssure has signed a research collaboration agreement with the Icahn School of Medicine at Mount Sinai, in New York, which will facilitate the performance of a new validation study utilising OncoAssure’s Prostate Cancer Test and curated clinical samples from Icahn School of Medicine at Mount Sinai.
The Icahn School of Medicine at Mount Sinai is an international leader in biomedical education, research, and patient care and is the medical school for the Mount Sinai Health System in New York, which includes seven hospital campuses.
OncoAssure’s prostate test helps assess the risk of aggressive disease and disease recurrence and can be used at two key decision points in the prostate cancer pathway, post-biopsy and post-surgery.
It was developed using a novel process that identifies ‘master driver’ genes that are strong indicators of disease progression. The test also incorporates the widely used CAPRA (Cancer of the Prostate Risk Assessment) score in the result, allowing seamless integration into current care pathways.
The new study will analyse prostate biopsy tissue from men with low- to intermediate-risk prostate cance with the primary objective of assessing the prognostic value of the OncoAssure Prostate Test in a representative cohort. The study will also evaluate the added prognostic value of the OncoAssure Prostate Test beyond routinely used clinical and pathological information.
Des O’Leary, CEO, OncoAssure (pictured), said: “By applying our innovative OncoAssure Prostate technology in collaboration with the Icahn School of Medicine, we aim to generate additional evidence supporting the potential of the OncoAssure Prostate Cancer Test to both reduce unnecessary interventions and provide critical lead time for treating the most aggressive tumors. This work will build on prior studies conducted in collaboration with Lund University in Sweden.”
TechCentral Reporters
Subscribers 0
Fans 0
Followers 0
Followers